全文获取类型
收费全文 | 2539篇 |
免费 | 141篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 103篇 |
妇产科学 | 138篇 |
基础医学 | 350篇 |
口腔科学 | 39篇 |
临床医学 | 209篇 |
内科学 | 503篇 |
皮肤病学 | 39篇 |
神经病学 | 171篇 |
特种医学 | 191篇 |
外国民族医学 | 1篇 |
外科学 | 381篇 |
综合类 | 15篇 |
一般理论 | 1篇 |
预防医学 | 225篇 |
眼科学 | 55篇 |
药学 | 176篇 |
中国医学 | 1篇 |
肿瘤学 | 83篇 |
出版年
2023年 | 10篇 |
2022年 | 27篇 |
2021年 | 57篇 |
2020年 | 37篇 |
2019年 | 59篇 |
2018年 | 75篇 |
2017年 | 38篇 |
2016年 | 42篇 |
2015年 | 49篇 |
2014年 | 65篇 |
2013年 | 116篇 |
2012年 | 118篇 |
2011年 | 132篇 |
2010年 | 110篇 |
2009年 | 83篇 |
2008年 | 114篇 |
2007年 | 102篇 |
2006年 | 132篇 |
2005年 | 105篇 |
2004年 | 88篇 |
2003年 | 82篇 |
2002年 | 86篇 |
2001年 | 70篇 |
2000年 | 86篇 |
1999年 | 67篇 |
1998年 | 40篇 |
1997年 | 34篇 |
1996年 | 34篇 |
1995年 | 36篇 |
1994年 | 38篇 |
1993年 | 27篇 |
1992年 | 38篇 |
1991年 | 36篇 |
1990年 | 40篇 |
1989年 | 41篇 |
1988年 | 42篇 |
1987年 | 30篇 |
1986年 | 30篇 |
1985年 | 44篇 |
1984年 | 24篇 |
1983年 | 22篇 |
1982年 | 29篇 |
1981年 | 14篇 |
1980年 | 19篇 |
1978年 | 9篇 |
1977年 | 13篇 |
1976年 | 17篇 |
1975年 | 17篇 |
1974年 | 17篇 |
1973年 | 14篇 |
排序方式: 共有2692条查询结果,搜索用时 15 毫秒
101.
López-Requena A Bestagno M Mateo de Acosta C Cesco-Gaspere M Vázquez AM Pérez R Burrone OR 《Molecular immunology》2007,44(11):2915-2922
P3 mAb is an IgM monoclonal antibody specific for N-glycolyl-containing gangliosides. The immunogenicity of the P3 idiotype has been previously described by immunizing syngeneic BALB/c mice with the purified murine IgM or the mouse-human chimeric IgG antibody. In the present work we study the antibody response against the idiotype of P3 mAb through immunization with DNA. We used small immune proteins (SIP) consisting on the idiotype in the scFv format, covalently linked to gamma1CH3, the self-dimerizing domain of murine IgG1. SIPs were previously shown to be appropriate to induce specific anti-idiotypic responses. By gene gun immunization, a polyspecific response was occasionally generated, particularly with the P3 idiotype. A single shot of DNA was sufficient to induce a strong and long-lasting anti-P3 idiotype response. In addition, by delivery of the same DNA construct with a recombinant adeno-associated virus the unique immunogenicity of the P3 idiotype was demonstrated. The requirement of T cells in the anti-P3 idiotype response was indicated by the lack of P3-specific anti-idiotypic antibodies following immunization of both, allogeneic C57BL/6 and athymic BALB/c mice. 相似文献
102.
103.
Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants
下载免费PDF全文
![点击此处可从《Antimicrobial agents and chemotherapy》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Zorrilla CD Van Dyke R Bardeguez A Acosta EP Smith B Hughes MD Huang S Watts DH Heckman B Jiménez E McSherry G Mofenson L 《Antimicrobial agents and chemotherapy》2007,51(6):2208-2210
Saquinavir boosted with low-dose ritonavir given with zidovudine and lamivudine was well tolerated by pregnant women and their infants. All mothers had <400 human immunodeficiency virus type 1 RNA copies/ml at delivery. Two had elevated liver transaminases and amylase. Seven infant adverse events were possibly treatment related (anemia, neutropenia, and hyperbilirubinemia). 相似文献
104.
First Epidemiologic Study in Argentina of the Prevalence of BK Viruria in Kidney Transplant Patients
R. Schiavelli R. Bonaventura M.C. Rial H. Petrone G. Soler Pujol L.J. Gaite M. Acosta A. Gutierrez F. Acosta G. Valdez P. Raffaele G. Chanta M. Perez L. Potes E. Suso G. Cremades J. Ibañez N. Imperiali M.C. Freire 《Transplantation proceedings》2014,46(9):3010-3014
BackgroundThe worldwide seroprevalence of human BK polyomavirus (BKV) in adults is 80%. About 10%–60% of renal transplant recipients experience BKV infection, nephropathy of the graft may occur in 5% of the cases, and up to 45% lose the graft. The aim of this work was to describe the prevalence of BK viruria during the 1st year after transplantation.MethodsAn epidemiologic multicenter cross-sectional study was carried out in consecutive patients at each site with kidney transplantation from August 2011 to July 2012. Clinically significant viruria was defined as >107 copies/mL. Viral DNA was extracted with the use of silica columns. Quantification was performed with the use of real-time polymerase chain reaction with primers that amplify a fragment of the large T-antigen gene and with a specific Taqman-MGB probe for BKV. For each assay, a standard curve with a quantified plasmid was included.ResultsOf 402 renal transplant recipients at 18 renal transplant sites, we analyzed 382; median age was 46.33 years, and 46.40% were female. The median of the temporal distribution for urine samples was 153 days. BK virus was detected in 50/382 samples (13%), 18 with values >107 copies/mL (4.7%). The median of the distribution of positive values was 123 days and the highest frequency of positive values was in months 3–7. The conditions of recipient older than 34 years and donor older than 41 years were the only ones that showed statistically significant association with BK viruria. No association with any specific immunosuppressive drug was observed.ConclusionsThis is the first multicenter study conducted in Argentina to determine the prevalence of BK viruria in renal transplant recipients. Because of the growing number of the population susceptible to this infection, it is important to register and describe data about its epidemiology and associated risk factors. 相似文献
105.
Early,Middle, or Late Administration of Zoledronate Alleviates Spontaneous Nociceptive Behavior and Restores Functional Outcomes in a Mouse Model of CFA‐Induced Arthritis
下载免费PDF全文
![点击此处可从《Drug development research》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Carlos Eduardo Morado‐Urbina Perla Abigail Alvarado‐Vázquez Rosa Mariana Montiel‐Ruiz Rosa Issel Acosta‐González Gabriela Castañeda‐Corral Juan Miguel Jiménez‐Andrade 《Drug development research》2014,75(7):438-448
Preclinical Research |
106.
Jessica Fallon Campbell Shweta Shah Poyyapakkam Srivaths Alisa A. Acosta 《Journal of clinical hypertension (Greenwich, Conn.)》2021,23(2):265
2017 pediatric blood pressure (BP) guidelines applied adult BP norms to define clinic hypertension (HTN) in patients ≥ 13 years. 2014 pediatric ambulatory BP monitor (ABPM) guidelines recommend age‐ and sex‐specific percentile norms for patients < 18 years. The authors evaluated reclassification of HTN when applying adult ABPM norms in patients ≥ 13 years and assessed the association of left ventricular hypertrophy (LVH) with HTN. Charts of patients 13–17 years with ABPM 9/2018–5/2019 were reviewed for sex, age, height, weight, BP medication, ABPM results, and left ventricular mass index (LVMI). American Heart Association 2005 (AHA 2005), AHA 2017 (AHA 2017), and European Society of Hypertension 2018 (ESH 2018) guidelines for adult ABPM were compared with 2014 AHA pediatric norms (pABPM). HTN was defined by each guideline using only ABPM. ABPM and clinic BP were used to classify white coat hypertension (WCH) and masked hypertension (MH). LVH was defined as LVMI > 51 g/m2.7. 272 patients had adequate ABPM. 124 patients also had echocardiogram. All adult norms resulted in significant reclassification of HTN. LVMI correlated significantly with systolic BP only. The odds of a patient with HTN having LVH was significant using AHA 2005 (OR: 8.75 [2.1, 36.4], p = .03) and ESH 2018 (OR: 4.94 [1, 24.3], p = .002). Significant reclassification of HTN occurs with all adult norms. HTN is significantly associated with LVH using AHA 2005 and ESH 2018. Applying pediatric norms for ABPM while using adult norms for clinic BP causes confusion. Guideline selection should balance misdiagnosis with over‐diagnosis. 相似文献
107.
108.
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811 总被引:23,自引:13,他引:23
Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR 《Blood》1995,85(8):2025-2037
The goal of this phase II multicenter clinical trial was to evaluate a new intensive chemotherapy program for adults with untreated acute lymphoblastic leukemia (ALL) and to examine prospectively the impact of clinical and biologic characteristics on the outcome. One hundred ninety-seven eligible and evaluable patients (16 to 80 years of age; median, 32 years of age) received cyclophosphamide, daunorubicin, vincristine, prednisone, and L-asparaginase; 167 patients (85%) achieved a complete remission (CR), 13 (7%) had refractory disease, and 17 (9%) died during induction. A higher CR rate was observed in younger patients (94% for those < 30 years old, 85% for those 30 to 59 years old, and 39% for those > or = 60 years old, P < .001) and in those who had a mediastinal mass (100%) or blasts with a T-cell immunophenotype. Eighty percent of B-lineage and 97% of T-cell ALL patients achieved a CR (P = .01). The coexpression of myeloid antigens did not affect the response rate or duration. Seventy percent of those with cytogenetic or molecular evidence of the Philadelphia (Ph) chromosome and 84% of those without such evidence achieved a CR (P = .11). Patients in remission received multiagent consolidation treatment, central nervous system prophylaxis, late intensification, and maintenance chemotherapy for a total of 24 months. After a median follow-up time of 43 months, the median survival for all 197 patients is 36 months; the median remission duration for the 167 CR patients is 29 months. Favorable pretreatment characteristics relative to remission duration or survival are younger age, the presence of a mediastinal mass or lymphadenopathy, a white blood cell count (WBC) less than 30,000/microL, L1 morphology, T or TMy immunophenotype, and the absence of the Ph chromosome. The estimates of the proportion surviving at 3 years are 69% for patients less than 30 years old, 39% for those 30 to 59 years old, 89% for those who had a mediastinal mass, 59% with WBC less than 30,000/microL, 63% with L1 morphology, 69% for T or TMy antigen expression, and 62% for those who lack the Ph chromosome. Fifteen patients (8%) had no unfavorable prognostic factors and have an estimated probability of survival at 5 years of 100% (95% confidence interval, 77% to 100%). This intensive chemotherapy regimen produces a high remission rate and a high proportion of durable remissions in adults with ALL. 相似文献
109.
High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients 总被引:1,自引:1,他引:1
High-dose intravenous gammaglobulin (polyvalent immunoglobulin G) has been shown to be of benefit in some patients with immune thrombocytopenic purpura (ITP), possibly by producing reticuloendothelial system blockade. We studied this approach in patients refractory to random donor platelet transfusion using an IV IgG preparation manufactured by the Swiss Red Cross. Eleven adult patients with acute leukemia received either 0.4 g IgG/kg/d intravenously X five days (four patients) or 0.6 g/kg/d X five days (seven patients). All patients had high levels of lymphocytotoxic antibody and poor responses to random donor platelets. Except for mild headaches in two patients, there were no side effects related to the IgG infusions. All patients had significant elevations of serum IgG on the day after completion of treatment. Either random donor or partially HLA-matched platelet transfusions were administered the day after and, in some cases, during the IgG therapy. No patient had an improvement in one hour posttransfusion platelet count increments. Two additional patients received pooled platelet concentrates incubated for 30 minutes at 37 degrees C with IgG at a final concentration of 3 g% prior to transfusions. These results indicate that high-dose IgG, an extremely expensive treatment, cannot be recommended for alloimmunized adults with leukemia. 相似文献
110.
High incidence of monoclonal proteins in the serum and urine of chronic lymphocytic leukemia patients 总被引:2,自引:0,他引:2
Chronic lymphocytic leukemia (CLL) is generally considered a nonsecretory B cell immunoproliferative disorder. Conventional electrophoretic and immunoelectrophoretic methods have revealed serum monoclonal proteins in less than 10% of these patients. However, there is increasing experimental evidence from in vitro studies demonstrating that CLL cells may secrete immunoglobulins, particularly free light chains. We examined the serum and urine of 36 consecutive CLL patients for monoclonal proteins using sensitive immunochemical methods (high resolution agarose gel electrophoresis combined with immunofixation). The results obtained were correlated with the Rai stage, quantitative immunoglobulin levels, and lymphocyte membrane immunoglobulin phenotype of the leukemic cells. Twenty-three monoclonal proteins were identified in the serum or urine of 22 patients, an incidence of 61%. Six patients had serum monoclonal proteins, seven had only urinary monoclonal proteins, and nine had monoclonal proteins in serum and urine. In every instance the monoclonal protein was the same light chain type as expressed on the leukemic cells. Our findings suggest that the monoclonal proteins observed in the serum or urine of CLL patients are secretory products of the tumor cells and that their discovery is a function of the sensitivity of the method used for their detection. 相似文献